Abstract
In recent years, phenotypic-based screens have become increasingly popular in drug discovery. A major challenge of this approach is that it does not provide information about the mechanism of action of the hits. This has led to the development of multiple strategies for target deconvolution. Thermal proteome profiling (TPP) allows for an unbiased search of drug targets and can be applied in living cells without requiring compound labeling. TPP is based on the principle that proteins become more resistant to heat-induced unfolding when complexed with a ligand, e.g., the hit compound from a phenotypic screen. The melting proteome is also sensitive to other intracellular events, such as levels of metabolites, post-translational modifications and protein-protein interactions. In this review, we describe the principles of this approach, review the method and its developments, and discuss its current and future applications. While proteomics has generally focused on measuring relative protein concentrations, TPP provides a novel approach to gather complementary information on protein stability not present in expression datasets. Therefore, this strategy has great potential not only for drug discovery, but also for answering fundamental biological questions.
Highlights
Current drug discovery generally starts by using a targetor a phenotypic-based approach for compound screening [1]
This review focuses on the principles of thermal proteome profiling (TPP), the recent advances in the method, and its possible future applications
Target identification by ligand stabilization (TILS), a technique based on similar principles to TPP, has recently shown that this method can be applied to bacteria and is not restricted to mammalian cells [50]
Summary
Current drug discovery generally starts by using a targetor a phenotypic-based approach for compound screening [1]. A number of strategies use mass spectrometry-based proteomics [9, 10] and are based on changes in target stability upon compound binding. These include, for example, drug affinity responsive target stability (DARTS) [11], stability of proteins from rates of oxidation (SPROX) [12,13,14], or thermal proteome profiling (TPP) [15,16,17,18].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.